Updates
** Applied Therapeutics' APLT.O shares fall 72.1% to $2.39, set for a record single-day drop
** The U.S. FDA on Wednesday declined to approve APLT's drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter cited "deficiencies in the clinical application" for the drug, called govorestat, APLT says
** Brokerage William Blair says the letter was "unexpected and disappointing" but believes it does not increase the regulatory risk for govorestat's approval for SORD deficiency, another rare genetic metabolic condition
** Including session's losses, stock down 28.4% YTD
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。